Humanwell Healthcare (SHA:600079) subsidiary Yichang Humanwell's application to market nalbuphine hydrochloride injection for a new use has been accepted for review by China's medical products administrator.
The drug, already approved for anesthesia induction and post-surgery pain since 2013, now seeks approval for analgesia in intensive care unit patients, according to a Tuesday filing with the Shanghai bourse.
Shares of the pharmaceutical company were up 2% Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments